Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.34 |
| ▸ | AHCY | P23526 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6386486 | 0.88 | PDE4A (0.37) | ADORA3ADORA2AADORA1ADORA2BAHCY | |
| SCHEMBL4834707 | 0.88 | PDE4A (0.37) | ADORA3ADORA2AADORA1ADORA2BAHCY | |
| SCHEMBL30544925 | 0.88 | ADORA2A (0.49) | ADORA3ADORA2AADORA1ADORA2BAHCY | |
| SCHEMBL6909391 | 0.87 | NPEPPS (0.39) | LMNA | |
| SCHEMBL10930706 | 0.82 | ACHE (0.38) | ADORA2A | |
| SCHEMBL5498228 | 0.81 | LMNA (0.37) | ADORA3ADORA2AADORA1ADORA2BLMNA | |
| SCHEMBL29606234 | 0.80 | PRKAB2 (0.52) | ADORA3ADORA2AADORA1TSHRLMNA | |
| SCHEMBL4948918 | 0.79 | LMNA (0.43) | ADORA3ADORA2AADORA1ADORA2BLMNA | |
| SCHEMBL9122994 | 0.78 | ADORA3 (0.37) | ADORA3ADORA2AADORA1ADORA2BAHCY | |
| SCHEMBL9122999 | 0.78 | ADORA3 (0.37) | ADORA3ADORA2AADORA1ADORA2BAHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113173961-B | Method for preparing adenosine | 远大生命科学(辽宁)有限公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022048680-A1 | METHOD FOR PREPARING AND PURIFYING ADENOSINE | 远大生命科学(辽宁)有限公司 | 2022-03-10 | — | — | WO | disclosed |
| EP-2707483-B1 | METHODS AND MATERIALS FOR NUCLEIC ACID MANIPULATION | RWTH AACHEN UNIV (DE) | 2017-10-18 | — | — | EP | disclosed |
| US-20120295311-A1 | Methods and Materials for Nucleic Acid Manipulation | BASF SE (DE) | 2012-11-22 | — | — | US | disclosed |
| CN-102675391-A | Technique for synthesizing adenosin by chemical method | SHANDONG KAISHENG NEW MATERIALS CO LTD | 2012-09-19 | — | — | CN | disclosed |
| US-7345164-B2 | Production method of 5′-acyloxynucleoside compound | AJINOMOTO CO., INC. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-20060014944-A1 | Processes for production of nucleosides | AJINOMOTO CO., INC. (JP) | 2006-01-19 | — | — | US | disclosed |
| EP-1589027-A1 | PROCESSES FOR PRODUCTION OF NUCLEOSIDES | Ajinomoto Co., Inc. (JP) | 2005-10-26 | — | — | EP | disclosed |
| US-20040230053-A1 | Production method of 5'-acyloxynucleoside compound | AJINOMOTO CO., INC. (JP) | 2004-11-18 | — | — | US | disclosed |
| EP-1471071-A1 | Production method of 5'-acyloxynucleoside compound | Ajinmoto Co., Inc. (JP) | 2004-10-27 | — | — | EP | disclosed |
| EP-0759925-A1 | ADENOSINE DERIVATIVES | SANDOZ LTD. (CH) | 1997-03-05 | — | — | EP | disclosed |
| US-5596094-A | Process for preparing 2' -0- alkyl adenosine derivatives | SANDOZ LTD. (CH) | 1997-01-21 | — | — | US | disclosed |
| WO-1995030683-A1 | ADENOSINE DERIVATIVES | SANDOZ LTD. (CH) | 1995-11-16 | — | — | WO | disclosed |
| US-5466793-A | Catalytic reducing of a nucleoside with hydrogen in the presence of palladium and recovering | AJINOMOTO CO., INC. (JP) | 1995-11-14 | — | — | US | disclosed |
| US-5290927-A | Process for preparing 2',3'-dideoxyadenosine | AJINOMOTO CO., INC. (JP) | 1994-03-01 | — | — | US | disclosed |
| WO-1990008147-A1 | PURINE NUCLEOSIDES, PROCESS FOR PRODUCING THEM, AND DRUGS CONTAINING THESE COMPOUNDS | BOEHRINGER MANNHEIM GMBH (DE) | 1990-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014944-A1 | Processes for production of nucleosides | NUDT1, NT5C3B, DNTT | ADORA3 445/4885ADORA2A 263/4885ADORA1 251/4885 |
| US-20040230053-A1 | Production method of 5'-acyloxynucleoside compound | ALKBH2, DUT, ALKBH1 | ADORA3 1219/4885ADORA2A 1486/4885ADORA1 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.